VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 187 filers reported holding VAXCYTE INC in Q1 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $44,613,793 | -21.8% | 1,190,336 | 0.0% | 0.73% | -35.1% |
Q4 2022 | $57,076,611 | -27.6% | 1,190,336 | -63.8% | 1.12% | -13.2% |
Q3 2022 | $78,852,000 | -1.2% | 3,285,504 | -10.4% | 1.29% | +4.7% |
Q2 2022 | $79,803,000 | -18.5% | 3,667,425 | -9.6% | 1.23% | +1.9% |
Q1 2022 | $97,930,000 | -2.2% | 4,055,092 | -3.6% | 1.21% | +21.1% |
Q4 2021 | $100,098,000 | – | 4,207,575 | – | 1.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |